pDONR223-MET Citations (7)

Originally described in: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA Nature. 2010 Dec 16;468(7326):968-72. doi: 10.1038/nature09627 PubMed Journal

---

Articles Citing pDONR223-MET

Articles
ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53. Sullivan KD, Padilla-Just N, Henry RE, Porter CC, Kim J, Tentler JJ, Eckhardt SG, Tan AC, DeGregori J, Espinosa JM. Nat Chem Biol. 2012 Jul;8(7):646-54. doi: 10.1038/nchembio.965. Epub 2012 Jun 3. PubMed
Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer. Kwak EL, Ahronian LG, Siravegna G, Mussolin B, Godfrey JT, Clark JW, Blaszkowsky LS, Ryan DP, Lennerz JK, Iafrate AJ, Bardelli A, Hong TS, Corcoran RB. Cancer Discov. 2015 Dec;5(12):1271-81. doi: 10.1158/2159-8290.CD-15-0748. Epub 2015 Oct 2. PubMed
JNK Pathway Activation Modulates Acquired Resistance to EGFR/HER2-Targeted Therapies. Manole S, Richards EJ, Meyer AS. Cancer Res. 2016 Sep 15;76(18):5219-28. doi: 10.1158/0008-5472.CAN-16-0123. Epub 2016 Jul 22. PubMed
The OncoPPi network of cancer-focused protein-protein interactions to inform biological insights and therapeutic strategies. Li Z, Ivanov AA, Su R, Gonzalez-Pecchi V, Qi Q, Liu S, Webber P, McMillan E, Rusnak L, Pham C, Chen X, Mo X, Revennaugh B, Zhou W, Marcus A, Harati S, Chen X, Johns MA, White MA, Moreno C, Cooper LA, Du Y, Khuri FR, Fu H. Nat Commun. 2017 Feb 16;8:14356. doi: 10.1038/ncomms14356. PubMed
Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers. Kelso TWR, Porter DK, Amaral ML, Shokhirev MN, Benner C, Hargreaves DC. Elife. 2017 Oct 2;6. pii: 30506. doi: 10.7554/eLife.30506. PubMed
Oncogenic Kinase-Induced PKM2 Tyrosine 105 Phosphorylation Converts Nononcogenic PKM2 to a Tumor Promoter and Induces Cancer Stem-like Cells. Zhou Z, Li M, Zhang L, Zhao H, Sahin O, Chen J, Zhao JJ, Songyang Z, Yu D. Cancer Res. 2018 May 1;78(9):2248-2261. doi: 10.1158/0008-5472.CAN-17-2726. Epub 2018 Feb 12. PubMed
Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro. Fujino T, Kobayashi Y, Suda K, Koga T, Nishino M, Ohara S, Chiba M, Shimoji M, Tomizawa K, Takemoto T, Mitsudomi T. J Thorac Oncol. 2019 Jul 3. pii: S1556-0864(19)30551-9. doi: 10.1016/j.jtho.2019.06.023. PubMed

If you have published an article using this material, please email us at to have your article added to this page.